AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8808185 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 9
Study 8808185 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation
Number of subjects: 9
Study 8808185 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP
Number of subjects: 9
Study 8808185 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 9
Study 8808185 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study 1878184 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction coaching
Number of subjects: 40
Study 1878184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 6114677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 2%
Number of subjects: 0
Study 6114677 — intervention group
Group type: COMPARATOR
Intervention: Labetalol 1%
Number of subjects: 0
Study 31310470 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 mg/kg lorazepam per os (PO) twice before the operation
Number of subjects: 61
Study 31310470 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anxiolytic premedication)
Number of subjects: 61
Study 29352723 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4684
Study 29352723 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4684
Study 25476995 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral ibandronate
Number of subjects: 0
Study 25476995 — intervention group
Group type: COMPARATOR
Intervention: 1.0 mg i.v. ibandronate
Number of subjects: 0
Study 25189523 — intervention group
Group type: EXPERIMENTAL
Intervention: H‐HOPE intervention
Number of subjects: 198
Study 25189523 — intervention group
Group type: COMPARATOR
Intervention: Attention Control
Number of subjects: 198
Study 22251482 — intervention group
Group type: EXPERIMENTAL
Intervention: FBS0701 at 14.5 mg/kg/d
Number of subjects: 51
Study 22251482 — intervention group
Group type: EXPERIMENTAL
Intervention: FBS0701 at 29 mg/kg/d
Number of subjects: 51
Study 19177255 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 403
Study 19177255 — intervention group
Group type: COMPARATOR
Intervention: Transdermal E2/NETA 50 microg/140 microg
Number of subjects: 403
Study 17192289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SST and GHRH/arginine test
Number of subjects: 24
Study 17192289 — intervention group
Group type: COMPARATOR
Intervention: SST alone
Number of subjects: 24
Study 17192289 — intervention group
Group type: COMPARATOR
Intervention: GHRH/arginine test alone
Number of subjects: 24
Study 14999462 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive training for GPs
Number of subjects: 0
Study 14999462 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11666126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) at 120 mg daily
Number of subjects: 0
Study 11666126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA) at 60 mg daily
Number of subjects: 0
Study 11666126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9579130 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall injection of low-dose heparin
Number of subjects: 114
Study 9579130 — intervention group
Group type: COMPARATOR
Intervention: Upper limb injection of low-dose heparin
Number of subjects: 114
Study 7706983 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 14
Study 7706983 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 14
Study 2709252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk (breast-milk fortifier mixed with mother's milk)
Number of subjects: 59
Study 2709252 — intervention group
Group type: COMPARATOR
Intervention: Human milk (breast-milk only)
Number of subjects: 59
Study 1268451 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative reinforcement ('bad' and electric shock) with both female and male experimenters
Number of subjects: 80
Study 1268451 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement ('good') with male experimenter
Number of subjects: 80
Study 1268451 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement ('good') with female experimenter
Number of subjects: 80
Study 31312890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold snare polypectomy (CSP)
Number of subjects: 501
Study 31312890 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of the resection by a trainee
Number of subjects: 501
Study 28774885 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP with 5 mg iron (Fe group)
Number of subjects: 155
Study 28774885 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP with 7.5 g GOS and 5 mg iron (FeGOS group)
Number of subjects: 155
Study 28774885 — intervention group
Group type: COMPARATOR
Intervention: MNP without iron (control)
Number of subjects: 155
Study 26387721 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox Maze-IV procedure using the AtriCure Synergy bipolar radiofrequency ablation system
Number of subjects: 55
Study 23816760 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus carboplatin; S-1 at 80 mg/m²/day for 2 weeks, followed by 2 weeks of no treatment; Carboplatin at AUC 6 on day 8, repeated for 4-6 cycles of 28 days
Number of subjects: 17
Study 21639811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement
Number of subjects: 699
Study 21639811 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 699
Study 19878831 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.3% eyedrops
Number of subjects: 152
Study 19878831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5% eyedrops
Number of subjects: 152
Study 16924046 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% fluorouracil cream applied twice daily for 3 weeks
Number of subjects: 34
Study 16924046 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% trichloroacetic acid peel
Number of subjects: 34
Study 16924046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser resurfacing
Number of subjects: 34
Study 16924046 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 of 7 eligible patients who declined study-related treatment)
Number of subjects: 34
Study 15276393 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 8000
Study 15276393 — intervention group
Group type: COMPARATOR
Intervention: Teacher-led sex education
Number of subjects: 8000
Study 11167663 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.1, 0.2, 0.3 mg twice daily)
Number of subjects: 97
Study 11167663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 9042124 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ppm nitric oxide
Number of subjects: 23
Study 9042124 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm nitric oxide
Number of subjects: 23
Study 9042124 — intervention group
Group type: COMPARATOR
Intervention: Control period (15 minutes before and after treatment)
Number of subjects: 23
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk intervention group (n = 612)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: COMPARATOR
Intervention: Randomised control group (n = 610)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-participant low risk group (n = 593)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: Refused group (n = 867)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluded group (n = 563)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 612)
Number of subjects: 3313
Study 7488463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention and control groups combined
Number of subjects: 3313
Study 2145654 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg almitrine
Number of subjects: 6
Study 2145654 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg medroxyprogesterone
Number of subjects: 6
Study 2145654 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6
Study 6996483 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilatation and evacuation (D‐E)
Number of subjects: 100
Study 6996483 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic instillation of prostaglandin F2 alpha (PGF2 alpha)
Number of subjects: 100
Study 31843676 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous resection
Number of subjects: 1168
Study 31843676 — intervention group
Group type: COMPARATOR
Intervention: Staged resection
Number of subjects: 1168
Study 29686382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ten Top Tips (TTT)
Number of subjects: 75
Study 29686382 — intervention group
Group type: EXPERIMENTAL
Intervention: Do Something Different (DSD)
Number of subjects: 75
Study 29686382 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 75
Study 27379830 — intervention group
Group type: COMPARATOR
Intervention: No breakfast
Number of subjects: 33
Study 27379830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-carbohydrate breakfast
Number of subjects: 33
Study 27379830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein breakfast
Number of subjects: 33
Study 27379830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate/low-protein breakfast
Number of subjects: 33
Study 27379830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein breakfast
Number of subjects: 33
Study 23122840 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU of oxytocin followed by an infusion of 2.5 UI×h(‐1)
Number of subjects: 104
Study 23122840 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 20 IU oxytocin at a rate of 700 mUI×min(‐1) followed later by 10 UI×h(‐1)
Number of subjects: 104
Study 23122840 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg bolus dose of carbetocin
Number of subjects: 104
Study 21147188 — intervention group
Group type: EXPERIMENTAL
Intervention: 15IPM
Number of subjects: 20
Study 21147188 — intervention group
Group type: EXPERIMENTAL
Intervention: 30IPM
Number of subjects: 20
Study 21147188 — intervention group
Group type: COMPARATOR
Intervention: noIPM
Number of subjects: 20
Study 21147188 — intervention group
Group type: EXPERIMENTAL
Intervention: 15IPM vs 30IPM
Number of subjects: 20
Study 19054496 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg intravitreal triamcinolone acetonide (TA)
Number of subjects: 40
Study 19054496 — intervention group
Group type: COMPARATOR
Intervention: 40 mg orbital floor triamcinolone acetonide (TA)
Number of subjects: 40
Study 17601892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 299
Study 17601892 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 299
Study 15336749 — intervention group
Group type: EXPERIMENTAL
Intervention: High elevation at home
Number of subjects: 0
Study 15336749 — intervention group
Group type: COMPARATOR
Intervention: Simple sling
Number of subjects: 0
Study 11504984 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 211
Study 11504984 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (PI)
Number of subjects: 211
Study 9006811 — intervention group
Group type: COMPARATOR
Intervention: Extended-release gemfibrozil (1200 mg/day) for 3 months
Number of subjects: 884
Study 9006811 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular gemfibrozil (1200 mg/day) for 6 months
Number of subjects: 884
Study 1338215 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75% THC
Number of subjects: 0
Study 1338215 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.55% THC
Number of subjects: 0
Study 1338215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6376209 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg plus triamterene 50 mg
Number of subjects: 88
Study 6376209 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone 50 mg
Number of subjects: 88
Study 31085948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP < 140 mmHg)
Number of subjects: 3233
Study 31085948 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (SBP < 180 mmHg)
Number of subjects: 3233
Study 28520924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg
Number of subjects: 10372
Study 28520924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 10372
Study 28520924 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 10372
Study 27056899 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/T (epirubicin, cyclophosphamide and paclitaxel)
Number of subjects: 0
Study 27056899 — intervention group
Group type: COMPARATOR
Intervention: CEF (cyclophosphamide, epirubicin and flurouracil)
Number of subjects: 0
Study 24643119 — intervention group
Group type: EXPERIMENTAL
Intervention: 18-Hz stimulation of the left dorsolateral prefrontal cortex (PFC)
Number of subjects: 13
Study 24643119 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz stimulation of the primary motor cortex (MC)
Number of subjects: 13
Study 24643119 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 22295813 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant acupuncture and nearby tuina therapy (30 treatments)
Number of subjects: 64
Study 22295813 — intervention group
Group type: COMPARATOR
Intervention: Calcium Carbonate D, Tablet (orally for 12 weeks)
Number of subjects: 64
Study 20814848 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg od
Number of subjects: 76
Study 20814848 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg od
Number of subjects: 76
Study 17491103 — intervention group
Group type: EXPERIMENTAL
Intervention: AVJAP
Number of subjects: 48
Study 17491103 — intervention group
Group type: COMPARATOR
Intervention: MED
Number of subjects: 48
Study 15709830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Coping With Depression (CWD‐A) course
Number of subjects: 93
Study 15709830 — intervention group
Group type: COMPARATOR
Intervention: Life skills control condition
Number of subjects: 93
Study 11896100 — intervention group
Group type: EXPERIMENTAL
Intervention: EU/5-FU (11.5 mg/m²/1.15 mg/m² twice daily for 28 days every 35 days)
Number of subjects: 981
Study 11896100 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV (425 mg/m²/20 mg/m² once daily for 5 days every 28 days)
Number of subjects: 981
Study 11896100 — intervention group
Group type: EXPERIMENTAL
Intervention: EU/5-FU
Number of subjects: 981
Study 11896100 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 981
Study 10661600 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 47
Study 10661600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 10661600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test
Number of subjects: 47
Study 10661600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine challenge test with length of illness history
Number of subjects: 47
Study 8677155 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant enzymes (glutathione reductase and glutathione S‐transferase)
Number of subjects: 0
Study 2008971 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation method (Compur M 1100)
Number of subjects: 10
Study 2008971 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugation method (Stat‐Crit)
Number of subjects: 10
Study 2008971 — intervention group
Group type: COMPARATOR
Intervention: Reference method (Coulter counter Model S + 2)
Number of subjects: 10
Study 2008971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution with dextran 40
Number of subjects: 10
Study 2008971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilution with fluid modified gelatin (Plasmion)
Number of subjects: 10
Study 2008971 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistivity technique for samples diluted with gelatin
Number of subjects: 10
Study 7008799 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 2
Study 7008799 — intervention group
Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 2
Study 30753252 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 674
Study 30753252 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet
Number of subjects: 674
Study 27612996 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol efflux capacity
Number of subjects: 1147
Study 27544544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU daily from 26 to 28 weeks of gestation until childbirth)
Number of subjects: 169
Study 27544544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 24756487 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed, humidified carbon dioxide
Number of subjects: 148
Study 24756487 — intervention group
Group type: COMPARATOR
Intervention: Standard carbon dioxide
Number of subjects: 148
Study 21639722 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised aerobic training for 50 minutes four times per week during 6 months
Number of subjects: 176
Study 19731176 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training and diet education (INT group)
Number of subjects: 24
Study 19731176 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous aerobic exercise and diet education (CON group)
Number of subjects: 24
Study 19731176 — intervention group
Group type: COMPARATOR
Intervention: Diet education only (DIET group)
Number of subjects: 24
Study 17499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 552
Study 17499406 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of quadrivalent HPV vaccine
Number of subjects: 552
Study 17499406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 14983409 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg androstenedione
Number of subjects: 3
Study 14983409 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg androstenedione
Number of subjects: 3
Study 14983409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 11601954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatments
Number of subjects: 0
Study 11601954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacologic treatments
Number of subjects: 0
Study 11601954 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatments
Number of subjects: 0
Study 11601954 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional and subspecialty variations
Number of subjects: 0
Study 9972083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal catheter
Number of subjects: 99
Study 9972083 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 99
Study 7846253 — intervention group
Group type: EXPERIMENTAL
Intervention: Light therapy
Number of subjects: 80
Study 7846253 — intervention group
Group type: COMPARATOR
Intervention: None (other DSM-III-R criteria)
Number of subjects: 80
Study 3370523 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture-vapour-permeable film (MVPF)
Number of subjects: 0
Study 3370523 — intervention group
Group type: COMPARATOR
Intervention: Silver sulphadiazine
Number of subjects: 0
Study 28732813 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa
Number of subjects: 25
Study 28732813 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica sinensis
Number of subjects: 25
Study 28732813 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 25
Study 28732813 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with Curcuma longa
Number of subjects: 25
Study 28732813 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with Angelica sinensis
Number of subjects: 25
Study 28732813 — intervention group
Group type: COMPARATOR
Intervention: Aspirin with Panax ginseng
Number of subjects: 25
Study 28732813 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuma longa, Angelica sinensis, Panax ginseng
Number of subjects: 25
Study 25109412 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release guanfacine (4 mg)
Number of subjects: 83
Study 25109412 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release guanfacine (8 mg)
Number of subjects: 83
Study 25109412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25109412 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 83
Study 23294775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (dula, LY2189265)
Number of subjects: 0
Study 23294775 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose design
Number of subjects: 0
Study 21410033 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides/short-chain triglycerides (MCT/LCT) physical mixture
Number of subjects: 0
Study 21410033 — intervention group
Group type: COMPARATOR
Intervention: Four-component intravenous lipid emulsion (LCT, MCT, Olive-oil and Fish-oil)
Number of subjects: 0
Study 17668982 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 47
Study 17668982 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 47
Study 17668982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15830009 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN)
Number of subjects: 856
Study 15830009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 856
Study 15830009 — intervention group
Group type: COMPARATOR
Intervention: Control group (Hydroxyurea alone)
Number of subjects: 856
Study 15830009 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan
Number of subjects: 856
Study 12102380 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0